secwatch.observer — SEC 8-K summary
======================================

Issuer:     Anika Therapeutics, Inc. (ANIK)
CIK:        0000898437
Form:       8-K
Filed at:   2025-04-10T23:59:59+00:00
Accession:  0001171843-25-002148
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Anika Therapeutics announces departure of COO Anne Nunes, eliminates position
-----------------------------------------------------------------------------

- Anne Nunes departs as Chief Operations Officer effective April 25, 2025.
- She receives severance per her Executive Retention Agreement (filed as Exhibit 10.14 to 10-K).
- Stephen Griffin (EVP, CFO, COO) assumes manufacturing and operations functions.
- Company eliminates Chief Operations Officer role; no replacement planned.
- Griffin's annual compensation remains unchanged.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/898437/000117184325002148/0001171843-25-002148-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/898437/000117184325002148/f8k_041025.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-002148

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer